You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Autism Treatment The Pivotal Skills Trainer
SBC: ACCELERATIONS EDUCATIONAL SOFTWARE Topic: N/ADESCRIPTION (provided by applicant): This STTR (Phase 1) project begins the translation of untapped scientific findings into an improved software tool for teaching children with autism spectrum disorders and other disabilities. The project evaluates a package to train teachers to use software called the Pivotal Skills Trainer and examines whether doing so improves preschoolers' functional communic ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Autism Education and Treatment with PowerPoint Software
SBC: ACCELERATIONS EDUCATIONAL SOFTWARE Topic: N/ADESCRIPTION (provided by applicant): PowerPoint(R) multimedia software is ubiquitous in our schools but its capacity for teaching children with autism spectrum and related disorders barely has been realized. This STTR (Phase I) project will begin to change this state of affairs by researching and developing empirically derived multimedia teaching tools. Encouraged by early-stage feasibility work, ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Discovery of Anti-Bioweapon Agents in BAC Libraries
SBC: EMETAGEN, LLC. Topic: N/ADESCRIPTION (provided by applicant): Antibiotics are an essential component in bio-defense preparedness. Soil microorganisms were a major source of antibiotics during the 20th century, yet antibiotic discovery is now severely limited. A primary reason is that drug discovery from microorganisms has been confined to those microbes that can be recovered by laboratory cultivation, yielding high rates ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Novel Treatment for Septicemia Targets A1 ARs
SBC: ENDACEA, INC Topic: N/ADESCRIPTION (provided by applicant): Septicemia is a medical syndrome characterized by an overwhelming systemic response to infection that can rapidly lead to shock, organ failure and death. In the U.S. septicemia is the 10th leading cause of death overall with over 750,000 cases and 215,000 deaths each year and accounts for $17 billion in annual health care expenditures. Following its release fr ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Detecting Early Emerging Drug-Resistant HIV Populations
SBC: ERAGEN BIOSCIENCES, INC. Topic: N/ADESCRIPTION (provided by applicant): Treatment of human immunodeficiency virus type 1 (HIV) infection with antiretroviral agents invariably leads to selection and accumulation of drug-resistant mutants that arise due to the intrinsically low fidelity of HIV polymerase. Early detection of these growing variants may be clinically relevant. Before the level of clinical importance can be ascertained, ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Pharmacophylogenomic Dates for the Master Catalog
SBC: ERAGEN BIOSCIENCES, INC. Topic: N/ADESCRIPTION (provided by applicant): This project will enhance the MASTERCATALOG, EraGen's product that combines an evolutionarily organized protein sequence database with tools to enable phylogenomics analysis. This will help maintain the commercial advantage of the MASTERCATALOG over public databases and tools, and help ensure that the MASTERCATALOG continues to enjoy its status as the "best in ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Pharmacotherapy for Opiate Addiction and Toxicity
SBC: ION TECHNOLOGIES, INC. Topic: N/ADESCRIPTION (provided by applicant): Morphine and other opiate drugs are widely used to treat severe pain but the addiction and side effects they produce often limit their use. The goal of this research is to develop a novel treatment for morphine addiction and toxicity based on an endogenous peptide, glycyl-glutamine (Gly-GIn). Gly-GIn is synthesized in brain from the opioid peptide, beta-endorph ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Modified HER-2 Tumor Antigens for Vaccination in Cancer
SBC: L2 DIAGNOSTICS LLC Topic: N/ADESCRIPTION (provided by applicant): The proposed studies are aimed at developing a new tumor immunotherapy by using isoaspartyl-modified peptides to break immune tolerance to "self" tumor antigens on breast cancer cells. Most tumor antigens have been characterized as normal, non-mutated self-peptides, linking the concepts of autoimmunity with the development of tumor immunity. Previous studies de ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Isoaspartyl Modified Tumor Antigens for Vaccination
SBC: L2 DIAGNOSTICS LLC Topic: N/ADESCRIPTION (provided by applicant): This proposal will take advantage of several unique observations made in understanding the properties of self proteins that regulate the development of autoimmune responses. In attempts to define cryptic self peptides of lupus autoantigens, we found that a particular post-translational modification of a self peptide elicited strong B and T cell autoimmunity. T ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Virulence Typing of Pseudomonas Clinical Isolates
SBC: L2 DIAGNOSTICS LLC Topic: N/ADESCRIPTION (provided by applicant): Pseudomonas aeruginosa is an opportunistic bacterial pathogen responsible for a significant proportion of serious hospital acquired infections. The organism has intrinsic resistance to most types of antibiotics and can readily acquire resistance to all clinically available antimicrobials, resulting in infections that are impossible to treat. P. aeruginosa colo ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health